Last reviewed · How we verify
NCT06862089
A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
trial in Retained Products of Conception in 120 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Fu Xing Hospital, Capital Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 23 October 2024 |
| Primary completion | 31 October 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Retained Products of Conception — all drugs for Retained Products of Conception →
- Miscarriage — all drugs for Miscarriage →
- Conservative Management — all drugs for Conservative Management →
Sponsor
Fu Xing Hospital, Capital Medical University
Who can join
Eligibility, female only, with Retained Products of Conception or Miscarriage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV). The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06862089
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retained Products of Conception
Currently open trials in the same condition.
- NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
- NCT07146659 — Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings · recruiting
- NCT07421895 — A Prospective Multicenter Observational Real-world Study of Retained Products of Conception · recruiting
- NCT05085067 — The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Rese · NA · recruiting
- NCT04804332 — Removal of Intrauterine Retained Products of Conception (RPOC) After Miscarriage Guided by Hysteroscopy Trial. A Randomi · NA · recruiting
Other Fu Xing Hospital, Capital Medical University trials
Trials by the same sponsor.
- NCT06608407 — Platelet Rich Plasma in the Prevention of Adhesion Reformation · NA · enrolling by invitation
- NCT05085067 — The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Rese · NA · recruiting
- NCT04835272 — Comparison of the Decannulation Protocol With Suctioning and Capping in Severe Acquired Brain Injury Patients · NA · unknown
- NCT04930913 — Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions · unknown
- NCT04936347 — Hysteroscopic "Hot Knife" and "Cold Knife" in the Treatment of the Intrauterine Adhesion · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06862089 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fu Xing Hospital, Capital Medical University
- Last refreshed: 15 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06862089.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing